Knight Therapeutics Inc. (TSX: GUD) announced that it has fully repaid all outstanding amounts under its revolving credit facility with National Bank of Canada and a syndicate of lenders. The facility was originally drawn for $60 million in June 2025 to help finance the company's acquisition of Paladin.
The repayment was funded through strong cash flow generated by Knight's operations in Canada and Latin America, demonstrating the company's financial discipline and operational strength. Despite the repayment, the revolving credit facility remains available, providing borrowing capacity of up to US$100 million, with an additional US$100 million accordion feature subject to certain conditions. This liquidity supports Knight's ongoing growth strategy across its pan-American pharmaceutical business.
The early repayment of debt reduces interest expenses and strengthens the company's balance sheet, positioning it for future acquisitions or investments. Knight Therapeutics focuses on acquiring or in-licensing and commercializing pharmaceutical products in Canada and Latin America, operating through subsidiaries United Medical, Biotoscana Farma, and Laboratorio LKM. The company's shares trade on the TSX under the symbol GUD.
For more details, the full press release can be accessed at https://ibn.fm/8eluB. Additional information about Knight Therapeutics is available on their website at www.knighttx.com.
This development underscores Knight's ability to generate significant cash flow and manage its debt effectively, which is crucial for sustaining growth in the competitive pharmaceutical industry. The repayment also reflects confidence in the company's operational performance and strategic direction.
